05Feb, 2025 CereVasc, Inc. Announces Results of Groundbreaking Clinical Study of the eShunt® System in the Treatment of Elderly Patients with Normal Pressure HydrocephalusCarlos Bonilla2025-07-19T20:10:54+00:00February 5th, 2025|Press Release|Read More
14Jan, 2025 CereVasc Announces First Enrollment in STRIDE Clinical Trial of the eShunt® System for Normal Pressure HydrocephalusCarlos Bonilla2025-07-19T19:59:04+00:00January 14th, 2025|Press Release|Read More
25Nov, 2024 CereVasc to Present at the Piper Sandler 36th Annual Healthcare ConferenceCarlos Bonilla2025-05-20T21:01:09+00:00November 25th, 2024|Press Release|Read More
25Sep, 2024 CereVasc Announces Journal of Molecular Therapy Publication Highlighting the eShunt® Platform as a CNS Gene Therapy Delivery MethodCarlos Bonilla2026-01-28T18:14:55+00:00September 25th, 2024|Press Release|Read More
17Sep, 2024 CereVasc Announces Enrollment of the 50th Patient in Pilot Studies of the eShunt® System for Normal Pressure Hydrocephaluscerevasc2024-10-14T16:19:05+00:00September 17th, 2024|Press Release|Read More
16Jul, 2024 CereVasc Announces Appointments of New DirectorsAdmin2024-07-18T18:46:24+00:00July 16th, 2024|Press Release|Read More
13May, 2024 CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure HydrocephalusAdmin2024-05-28T21:41:18+00:00May 13th, 2024|Press Release|Read More
07May, 2024 CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephaluscerevasc2024-05-28T21:43:24+00:00May 7th, 2024|Press Release|Read More
07Feb, 2024 CereVasc’s eShunt® System to be Presented at the International Stroke Conference by Dr. Pedro Lylykcerevasc2024-05-10T14:17:27+00:00February 7th, 2024|Press Release|Read More
23Jan, 2024 CereVasc’s eShunt® System Study Data Presented at the ABC WIN Seminarcerevasc2024-10-14T16:28:16+00:00January 23rd, 2024|Press Release|Read More
